Jiří Ferda
Jiří Ferda has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
Eva Ferdová
21 shared publicationsJan Baxa
Klinika zobrazovacích metod LF UK a FN Plzeň
15 shared publicationsBoris Kreuzberg
Department of Imaging Methods, Charles University Teaching Hospital Pilsen, Pilsen, Czech Republic
13 shared publications- Milan Hora
Department of Urology, Faculty of Medicine and University Hospital in Pilsen Charles University Pilsen Czech Republic
13 shared publications - Jan Baxa
Clinic of the Imaging Methods, University Hospital Plzen, Alej Svobody 80, 304 60 Plzeň, Czech Republic
10 shared publications Hynek Mírka
Department of the Imaging, University Hospital Pilsen and Charles University Medical Faculty in Pilsen, Czech Republic
9 shared publications
Latest Publications
- Open Access
Implementation and first results of the Czech nationwide prostate cancer screening pilot programme
Background: In 2022, the European Union recommended piloting organised prostate cancer screening. Subsequently, the Czech Republic launched a nationwide pilot programme fully reimbursed by public health insurance in January 2024 to reduce the high incidence of late-stage prostate cancer and the widespread unorganised prostate-specific antigen (PSA) testing. Objective: To describe the strategy, methodology, and first results of the Czech nationwide prostate cancer screening pilot programme. Methods: We analysed data from the first 12 months of the programme, which targets men aged 50–69 years without a previous prostate cancer diagnosis. General practitioners and urologists offer men an initial PSA test. Those with PSA ≥3.0 µg/l are referred to certified urologists, based on urology assessment selected for magnetic resonance imaging (MRI) and, if indicated, targeted biopsy. Reported key indicators are PSA testing coverage and overall use of pre-biopsy MRI. Key Findings and Limitations: Screening was offered to 150,498 men; PSA results were available for 146,109 (97.1%), 8.8% of whom had ≥3.0 µg/l. Within 6 months, 67.2% with PSA ≥3.0 µg/l underwent urological evaluation. From 2023 to 2024, the 2-year PSA testing rate rose from 47.4% to 53.3%, and pre-biopsy MRI use from 28.0% to 38.3% (10.3 percentage-point difference, 95% CI 8.3–12.2). Data on diagnostic outcomes are not yet analysed. Conclusions and Clinical Implications: These results demonstrate the feasibility of transforming widespread unorganised PSA testing to an organised screening programme with improved adherence to the recommended diagnostic pathway. Further evaluation to assess outcomes and efforts to reduce opportunistic testing will follow. Advancing Practice: What does this study add?: This is the first population-level evaluation of a nationwide organised prostate cancer screening programme in Central Europe. The findings demonstrate the feasibility of integrating a structured screening programme with PSA testing in routine primary care into a national health system. The programme improved adherence to guideline-based diagnostic pathways. Patient Summary: This report presents the initial results of a new nationwide, organised prostate cancer screening programme in the Czech Republic. The programme contributed to increased screening coverage in the target population (50-69 years) and improved the use of MRI before biopsy, which is now the recommended practice.
Open AccessImplementation and first results of the Czech nationwide prostate cancer screening pilot programme
Background: In 2022, the European Union recommended piloting organised prostate cancer screening. Subsequently, the Czech Republic launched a nationwide pilot programme fully reimbursed by public health insurance in January 2024 to reduce the high incidence of late-stage prostate cancer and the widespread unorganised prostate-specific antigen (PSA) testing. Objective: To describe the strategy, methodology, and first results of the Czech nationwide prostate cancer screening pilot programme. Methods: We analysed data from the first 12 months of the programme, which targets men aged 50–69 years without a previous prostate cancer diagnosis. General practitioners and urologists offer men an initial PSA test. Those with PSA ≥3.0 µg/l are referred to certified urologists, based on urology assessment selected for magnetic resonance imaging (MRI) and, if indicated, targeted biopsy. Reported key indicators are PSA testing coverage and overall use of pre-biopsy MRI. Key Findings and Limitations: Screening was offered to 150,498 men; PSA results were available for 146,109 (97.1%), 8.8% of whom had ≥3.0 µg/l. Within 6 months, 67.2% with PSA ≥3.0 µg/l underwent urological evaluation. From 2023 to 2024, the 2-year PSA testing rate rose from 47.4% to 53.3%, and pre-biopsy MRI use from 28.0% to 38.3% (10.3 percentage-point difference, 95% CI 8.3–12.2). Data on diagnostic outcomes are not yet analysed. Conclusions and Clinical Implications: These results demonstrate the feasibility of transforming widespread unorganised PSA testing to an organised screening programme with improved adherence to the recommended diagnostic pathway. Further evaluation to assess outcomes and efforts to reduce opportunistic testing will follow. Advancing Practice: What does this study add?: This is the first population-level evaluation of a nationwide organised prostate cancer screening programme in Central Europe. The findings demonstrate the feasibility of integrating a structured screening programme with PSA testing in routine primary care into a national health system. The programme improved adherence to guideline-based diagnostic pathways. Patient Summary: This report presents the initial results of a new nationwide, organised prostate cancer screening programme in the Czech Republic. The programme contributed to increased screening coverage in the target population (50-69 years) and improved the use of MRI before biopsy, which is now the recommended practice.
- Open Access
- 1 January 2026
- Published by Galen, spol. s r.o. in Česká radiologie
- Vol. 79 (4) , 237-244
Imaging of injured joints with ultra-high resolution using photon-counting CT
C?l: Zhodnotit mo?nosti zobrazen? poran?n? kloub? pomoc? photon-counting CT (PCCT) s ultravysok?m rozli?en?m. Metodika: Byla provedena anal?za akutn?ch vy?et?en? lokte, z?p?st? a ruky, d?le kolene, hlezna a nohy proveden?ch z d?vodu poran?n? ... C?l: Zhodnotit mo?nosti zobrazen? poran?n? kloub? pomoc? photon-counting CT (PCCT) s ultravysok?m rozli?en?m. Metodika: Byla provedena anal?za akutn?ch vy?et?en? lokte, z?p?st? a ruky, d?le kolene, hlezna a nohy proveden?ch z d?vodu poran?n? ...
- 1 January 2026
- Published by Galen, spol. s r.o. in Česká radiologie
- Vol. 79 (4) , 237-244
Open AccessImaging of injured joints with ultra-high resolution using photon-counting CT
C?l: Zhodnotit mo?nosti zobrazen? poran?n? kloub? pomoc? photon-counting CT (PCCT) s ultravysok?m rozli?en?m. Metodika: Byla provedena anal?za akutn?ch vy?et?en? lokte, z?p?st? a ruky, d?le kolene, hlezna a nohy proveden?ch z d?vodu poran?n? ... C?l: Zhodnotit mo?nosti zobrazen? poran?n? kloub? pomoc? photon-counting CT (PCCT) s ultravysok?m rozli?en?m. Metodika: Byla provedena anal?za akutn?ch vy?et?en? lokte, z?p?st? a ruky, d?le kolene, hlezna a nohy proveden?ch z d?vodu poran?n? ...
- Open Access
- 22 April 2025
- Published by Galen, spol. s r.o. in Česká radiologie
- Vol. 79 (1) , 15-24
The use of PET/CT and PET/MRI with the application of 18F-fluoroestradiol in the imaging of breast carcinoma
C?l: 18F-fluorestradiol je nov? radiofarmakum, kter? lze pou??t p?i zobrazov?n? karcinomu prsu, indikace v klinick?ch postupech je?t? nemaj? sv? pevn? m?sto, proto je c?lem studie posoudit klinick? v?znam zobrazen? karcinomu prsu estrogen-pozi... C?l: 18F-fluorestradiol je nov? radiofarmakum, kter? lze pou??t p?i zobrazov?n? karcinomu prsu, indikace v klinick?ch postupech je?t? nemaj? sv? pevn? m?sto, proto je c?lem studie posoudit klinick? v?znam zobrazen? karcinomu prsu estrogen-pozi...
- 22 April 2025
- Published by Galen, spol. s r.o. in Česká radiologie
- Vol. 79 (1) , 15-24
Open AccessThe use of PET/CT and PET/MRI with the application of 18F-fluoroestradiol in the imaging of breast carcinoma
C?l: 18F-fluorestradiol je nov? radiofarmakum, kter? lze pou??t p?i zobrazov?n? karcinomu prsu, indikace v klinick?ch postupech je?t? nemaj? sv? pevn? m?sto, proto je c?lem studie posoudit klinick? v?znam zobrazen? karcinomu prsu estrogen-pozi... C?l: 18F-fluorestradiol je nov? radiofarmakum, kter? lze pou??t p?i zobrazov?n? karcinomu prsu, indikace v klinick?ch postupech je?t? nemaj? sv? pevn? m?sto, proto je c?lem studie posoudit klinick? v?znam zobrazen? karcinomu prsu estrogen-pozi...
- Open Access
- 1 December 2023
- Published by Galen, spol. s r.o. in Česká radiologie
- Vol. 77 (4) , 203-212
Detection of prostate cancer - comparison of findings evaluated by an experienced radiologist or artificial intelligence using deep learning
C?l: Zhodnotit zku?enosti s hodnocen?m magnetick? rezonance prostaty pomoc?komer?n? dostupn?ho n?stroje um?l? inteligence s hlubok?m u?en?m. Metodika: Byla hodnocena skupina 100 vy?et?en? prostaty, kde byly n?lezyov??eny bu? operac?, nebo dlou... C?l: Zhodnotit zku?enosti s hodnocen?m magnetick? rezonance prostaty pomoc?komer?n? dostupn?ho n?stroje um?l? inteligence s hlubok?m u?en?m. Metodika: Byla hodnocena skupina 100 vy?et?en? prostaty, kde byly n?lezyov??eny bu? operac?, nebo dlou...
- 1 December 2023
- Published by Galen, spol. s r.o. in Česká radiologie
- Vol. 77 (4) , 203-212
Open AccessDetection of prostate cancer - comparison of findings evaluated by an experienced radiologist or artificial intelligence using deep learning
C?l: Zhodnotit zku?enosti s hodnocen?m magnetick? rezonance prostaty pomoc?komer?n? dostupn?ho n?stroje um?l? inteligence s hlubok?m u?en?m. Metodika: Byla hodnocena skupina 100 vy?et?en? prostaty, kde byly n?lezyov??eny bu? operac?, nebo dlou... C?l: Zhodnotit zku?enosti s hodnocen?m magnetick? rezonance prostaty pomoc?komer?n? dostupn?ho n?stroje um?l? inteligence s hlubok?m u?en?m. Metodika: Byla hodnocena skupina 100 vy?et?en? prostaty, kde byly n?lezyov??eny bu? operac?, nebo dlou...
- 25 March 2023
- Published by Elsevier in European Journal of Radiology
- Vol. 163, 110797
Neovascularization, vascular mimicry and molecular exchange: The imaging of tumorous tissue aggressiveness based on tissue perfusion
- 25 March 2023
- Published by Elsevier in European Journal of Radiology
- Vol. 163, 110797
Neovascularization, vascular mimicry and molecular exchange: The imaging of tumorous tissue aggressiveness based on tissue perfusion
- Open Access
- 1 March 2023
- Published by Galen, spol. s r.o. in Ceskoslovenska Pediatrie
- Vol. 78 (2) , 65-73
Hybrid imaging PET/MRI in pediatric patients
V p?ehledov?m ?l?nku jsou p?edlo?eny z?kladn? informace o vyu?it? hybridn?ho spojen? pozitronov? emisn? tomografie a magnetick? rezonance p?i zobrazov?n? d?tsk?ch pacient?, jsou vylo?eny z?kladn? technick? aspekty zobrazen?, logistika vy?et?en... V p?ehledov?m ?l?nku jsou p?edlo?eny z?kladn? informace o vyu?it? hybridn?ho spojen? pozitronov? emisn? tomografie a magnetick? rezonance p?i zobrazov?n? d?tsk?ch pacient?, jsou vylo?eny z?kladn? technick? aspekty zobrazen?, logistika vy?et?en...
- 1 March 2023
- Published by Galen, spol. s r.o. in Ceskoslovenska Pediatrie
- Vol. 78 (2) , 65-73
Open AccessHybrid imaging PET/MRI in pediatric patients
V p?ehledov?m ?l?nku jsou p?edlo?eny z?kladn? informace o vyu?it? hybridn?ho spojen? pozitronov? emisn? tomografie a magnetick? rezonance p?i zobrazov?n? d?tsk?ch pacient?, jsou vylo?eny z?kladn? technick? aspekty zobrazen?, logistika vy?et?en... V p?ehledov?m ?l?nku jsou p?edlo?eny z?kladn? informace o vyu?it? hybridn?ho spojen? pozitronov? emisn? tomografie a magnetick? rezonance p?i zobrazov?n? d?tsk?ch pacient?, jsou vylo?eny z?kladn? technick? aspekty zobrazen?, logistika vy?et?en...
- Open Access
- 30 December 2022
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 43 (1) , 449-453
Assessment of Prostate Carcinoma Aggressiveness: Relation to68Ga-PSMA-11-PET/MRI and Gleason Score
Background/Aim: To test the correlation of 68Ga-PSMA-11 uptake and the expression of PSMA (prostatic specific membrane antigen) with the Gleason score, apparent diffusion coefficient (ADC) and pharmacokinetic parameters obtained from dynamic contrast agent-enhanced MRI/PET. Patients and Methods: Forty newly diagnosed, therapy naïve patients with prostatic carcinoma (PC) (mean age of 56.7, range=34-79), who were referred for 68Ga-PSMA-11-PET/MRI for primary staging and had undergone radical prostatectomy (RAPE) were included in this prospective study. Their blood samples were tested for serum levels of prostate-specific antigen (PSA) and proPSA. The patients’ prostates were evaluated using whole-mount sections, which helped determine the extent and grade of the tumor; tests were performed to determine immunohistochemical PSMA expression. Results: A correlation between PSMA expression and the accumulation of 68Ga-PSMA-11 was found using the Spearman correlation coefficient (p=0.0011). A stronger correlation was found between Gleason patterns 3 or 4 and PSMA expression (p=0.06). Furthermore, the correlation of Gleason score with the overall 68Ga-PSMA-11 accumulation within the tumor or non-tumor tissue was found to be significant (p=0.0157). A significant relation was found only with the Kep elimination rate constant, which was stronger in Gleason pattern 4 than in Gleason pattern 3. A weaker correlation was found between the accumulation of 68Ga-PSMA-11 and Ktrans in Gleason pattern 4: the most significant relation being between ADCmin and Gleason pattern 3 and 4 (p=0.0074). The total size of the tumor correlated with levels of proPSA (p68Ga-PSMA-11 correlates well with the expression of PSMA. Gleason pattern 3 and 4 had a higher correlation with 68Ga-PSMA-11 levels than did Gleason pattern 5. Either no correlation, or a weak correlation, was established with pharmacokinetics.
- 30 December 2022
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 43 (1) , 449-453
Open AccessAssessment of Prostate Carcinoma Aggressiveness: Relation to68Ga-PSMA-11-PET/MRI and Gleason Score
Background/Aim: To test the correlation of 68Ga-PSMA-11 uptake and the expression of PSMA (prostatic specific membrane antigen) with the Gleason score, apparent diffusion coefficient (ADC) and pharmacokinetic parameters obtained from dynamic contrast agent-enhanced MRI/PET. Patients and Methods: Forty newly diagnosed, therapy naïve patients with prostatic carcinoma (PC) (mean age of 56.7, range=34-79), who were referred for 68Ga-PSMA-11-PET/MRI for primary staging and had undergone radical prostatectomy (RAPE) were included in this prospective study. Their blood samples were tested for serum levels of prostate-specific antigen (PSA) and proPSA. The patients’ prostates were evaluated using whole-mount sections, which helped determine the extent and grade of the tumor; tests were performed to determine immunohistochemical PSMA expression. Results: A correlation between PSMA expression and the accumulation of 68Ga-PSMA-11 was found using the Spearman correlation coefficient (p=0.0011). A stronger correlation was found between Gleason patterns 3 or 4 and PSMA expression (p=0.06). Furthermore, the correlation of Gleason score with the overall 68Ga-PSMA-11 accumulation within the tumor or non-tumor tissue was found to be significant (p=0.0157). A significant relation was found only with the Kep elimination rate constant, which was stronger in Gleason pattern 4 than in Gleason pattern 3. A weaker correlation was found between the accumulation of 68Ga-PSMA-11 and Ktrans in Gleason pattern 4: the most significant relation being between ADCmin and Gleason pattern 3 and 4 (p=0.0074). The total size of the tumor correlated with levels of proPSA (p68Ga-PSMA-11 correlates well with the expression of PSMA. Gleason pattern 3 and 4 had a higher correlation with 68Ga-PSMA-11 levels than did Gleason pattern 5. Either no correlation, or a weak correlation, was established with pharmacokinetics.
- Open Access
- 1 December 2022
- Published by Galen, spol. s r.o. in Česká radiologie
- Vol. 76 (4) , 222-230
Hybrid imaging PET/MRI in pediatric patients
V p?ehledov?m ?l?nku jsou p?edlo?eny z?kladn? informace o vyu?it? hybridn?hospojen? pozitronov? emisn? tomografie a magnetick? rezonance p?i zobrazov?n?d?tsk?ch pacient?, jsou vylo?eny z?kladn? technick? aspekty zobrazen?,logistika vy?et?en? i... V p?ehledov?m ?l?nku jsou p?edlo?eny z?kladn? informace o vyu?it? hybridn?hospojen? pozitronov? emisn? tomografie a magnetick? rezonance p?i zobrazov?n?d?tsk?ch pacient?, jsou vylo?eny z?kladn? technick? aspekty zobrazen?,logistika vy?et?en? i...
- 1 December 2022
- Published by Galen, spol. s r.o. in Česká radiologie
- Vol. 76 (4) , 222-230
Open AccessHybrid imaging PET/MRI in pediatric patients
V p?ehledov?m ?l?nku jsou p?edlo?eny z?kladn? informace o vyu?it? hybridn?hospojen? pozitronov? emisn? tomografie a magnetick? rezonance p?i zobrazov?n?d?tsk?ch pacient?, jsou vylo?eny z?kladn? technick? aspekty zobrazen?,logistika vy?et?en? i... V p?ehledov?m ?l?nku jsou p?edlo?eny z?kladn? informace o vyu?it? hybridn?hospojen? pozitronov? emisn? tomografie a magnetick? rezonance p?i zobrazov?n?d?tsk?ch pacient?, jsou vylo?eny z?kladn? technick? aspekty zobrazen?,logistika vy?et?en? i...
- 30 July 2022
- Published by Elsevier in European Journal of Radiology
- Vol. 154, 110458
The imaging of the hypoxic microenvironment in tumorous tissue using PET/CT and PET/MRI
- 30 July 2022
- Published by Elsevier in European Journal of Radiology
- Vol. 154, 110458
The imaging of the hypoxic microenvironment in tumorous tissue using PET/CT and PET/MRI
- Open Access
- 29 October 2021
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 2021, 1-6
VEILND (Video Endoscopic Inguinal Lymph Node Dissection) with Florescence Indocyanine Green (ICG): A Novel Technique to Identify the Sentinel Lymph Node in Men with ≥pT1G2 and cN0 Penile Cancer
Introduction. In men with pT1G2 cN0, penile cancer lymph node sampling is recommended with either (1) scintigraphically labelled Dynamic sentinel lymph node biopsy (DSLNB) or (2) modified inguinal lymph node dissection (MILND). Although DSLNB is a minimally invasive technique, the false negative rate can be about 10, and a further operative procedure is required if positive. Open MILND is a diagnostic and therapeutic option but has a much higher morbidity. A potential compromise is the technique of LND-VEILND (video endoscopic inguinal LND) that can be combined with ICG florescence marking of sentinel lymph node (SLN). We present a pilot study of ICG-VEILND. The aim was to validate the applicability of a combination ICG marking of SLN in VEILND (to increase probability to excise SLN) and determine the optimal timing and dosage of ICG. Materials and Methods. 15 patients with VEILND (24 groins) underwent ICG application with fluorescence near-infrared (NIR 803830nm) detection. ICG is applied subcutaneously adjacent to the penile cancer or residual stump of penis or suprapubic region (in a history of total penectomy: 5 cases). The dose of 1.25mg (ICG) was applied in one case with invisible SLN, the dose of 2.5mg in 1mL in 8 cases, and 5mg in the remaining 6 patients (10 groins). Results. Failure of marking SLN with ICG occurred in 25.0 of cases (6/24): due to application of 1.25mg ICG, extensive metastasis to SLN, in 4 cases, the cause was unknown (16.7, 4/24). In the short follow-up period, no local recurrence was seen in the pN0 ICG group. Conclusion. Fluorescence infrared image with ICG dye increases the probability of removal of the SLN during VEILND. The dose of ICG is 2.5 (5) mg diluted in 1ml and can be applied preoperatively even in the suprapubic region in men with a history of total penectomy, with an unexplainable failure of ICG marking in 16.7.
- 29 October 2021
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 2021, 1-6
Open AccessVEILND (Video Endoscopic Inguinal Lymph Node Dissection) with Florescence Indocyanine Green (ICG): A Novel Technique to Identify the Sentinel Lymph Node in Men with ≥pT1G2 and cN0 Penile Cancer
Introduction. In men with pT1G2 cN0, penile cancer lymph node sampling is recommended with either (1) scintigraphically labelled Dynamic sentinel lymph node biopsy (DSLNB) or (2) modified inguinal lymph node dissection (MILND). Although DSLNB is a minimally invasive technique, the false negative rate can be about 10, and a further operative procedure is required if positive. Open MILND is a diagnostic and therapeutic option but has a much higher morbidity. A potential compromise is the technique of LND-VEILND (video endoscopic inguinal LND) that can be combined with ICG florescence marking of sentinel lymph node (SLN). We present a pilot study of ICG-VEILND. The aim was to validate the applicability of a combination ICG marking of SLN in VEILND (to increase probability to excise SLN) and determine the optimal timing and dosage of ICG. Materials and Methods. 15 patients with VEILND (24 groins) underwent ICG application with fluorescence near-infrared (NIR 803830nm) detection. ICG is applied subcutaneously adjacent to the penile cancer or residual stump of penis or suprapubic region (in a history of total penectomy: 5 cases). The dose of 1.25mg (ICG) was applied in one case with invisible SLN, the dose of 2.5mg in 1mL in 8 cases, and 5mg in the remaining 6 patients (10 groins). Results. Failure of marking SLN with ICG occurred in 25.0 of cases (6/24): due to application of 1.25mg ICG, extensive metastasis to SLN, in 4 cases, the cause was unknown (16.7, 4/24). In the short follow-up period, no local recurrence was seen in the pN0 ICG group. Conclusion. Fluorescence infrared image with ICG dye increases the probability of removal of the SLN during VEILND. The dose of ICG is 2.5 (5) mg diluted in 1ml and can be applied preoperatively even in the suprapubic region in men with a history of total penectomy, with an unexplainable failure of ICG marking in 16.7.